4.7 Article

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis

期刊

ANNALS OF THE RHEUMATIC DISEASES
卷 80, 期 9, 页码 1168-1174

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2020-219446

关键词

-

资金

  1. Arthritis Research UK [19536, 18797]
  2. Wellcome Trust [076113]
  3. Oxford Comprehensive Biomedical Research Centre ankylosing spondylitis chronic disease cohort [A91202]
  4. National Natural Science Foundation of China [31821003]
  5. National Key Research and Development Project [2018AAA0100302]
  6. Shanghai Municipal Key Clinical Specialty [shslczdzk02602]
  7. Shanghai Science and Technology Development Funds [2020-SH-XY-2]
  8. Zhejiang Provincial Natural Science Foundation of China [LD18H120001LD]
  9. Health Research Council, New Zealand
  10. Economic and Social Research Council
  11. National Institute for Health Research (NIHR) Leeds Biomedical Research Centre
  12. Agence Nationale de Recherche GEMISA [ANR-10-MIDI-0002]
  13. Abbvie
  14. Pfizer
  15. UCB
  16. NHMRC
  17. ARC
  18. National Health and Medical Research Council (Australia) [566938, 569829, 1024879]
  19. Australian Cancer Research Foundation
  20. Rebecca Cooper Medical Research Foundation
  21. National Institute for Health Research Oxford Musculoskeletal Biomedical Research Unit
  22. NIHR Thames Valley Comprehensive Local Research
  23. Abbott Laboratories
  24. National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London
  25. Agence Nationale de la Recherche (ANR) [ANR-10-MIDI-0002] Funding Source: Agence Nationale de la Recherche (ANR)

向作者/读者索取更多资源

This study demonstrates that PRS has higher discriminatory capacity for AS than CRP, sacroiliac MRI or HLA-B27 status alone. For optimal performance, PRS should be developed and used in specific ethnic groups.
Objective We sought to test the hypothesis that Polygenic Risk Scores (PRSs) have strong capacity to discriminate cases of ankylosing spondylitis (AS) from healthy controls and individuals in the community with chronic back pain. Methods PRSs were developed and validated in individuals of European and East Asian ethnicity, using data from genome-wide association studies in 15 585 AS cases and 20 452 controls. The discriminatory values of PRSs in these populations were compared with other widely used diagnostic tests, including C-reactive protein (CRP), HLA-B27 and sacroiliac MRI. Results In people of European descent, PRS had high discriminatory capacity with area under the curve (AUC) in receiver operator characteristic analysis of 0.924.This was significantly better than for HLA-B27 testing alone (AUC=0.869), MRI (AUC=0.885) or C-reactive protein (AUC=0.700). PRS developed and validated in individuals of East Asian descent performed similarly (AUC=0.948). Assuming a prior probability of AS of 10% such as in patients with chronic back pain under 45 years of age, compared with HLA-B27 testing alone, PRS provides higher positive values for 35% of patients and negative predictive values for 67.5% of patients. For PRS, in people of European descent, the maximum positive predictive value was 78.2% and negative predictive value was 100%, whereas for HLA-B27, these values were 51.9% and 97.9%, respectively. Conclusions PRS have higher discriminatory capacity for AS than CRP, sacroiliac MRI or HLA-B27 status alone. For optimal performance, PRS should be developed for use in the specific ethnic groups to which they are to be applied.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据